COMMENTARY
Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
Keiji Nakamura, Ph. D.Pharma Forum InstituteKamakura, Japanhttp://www.pharma-fi.com/index.htmlPatent Expiration of BlockbustersAll blockbuster prescription drugs have a life cycle, and patents leave a drug to its fate. During the patent life, a branded product company enjoys a period of market exclusivity or…
To read the full story
COMMENTARY
- Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
- Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
April 28, 2026
- Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
April 24, 2026
- Challenges in a Post-AG Era: Ensuring a Reliable Supply System
April 6, 2026
- Japan’s FY2026 R&D Tax Credit Reform Wins Broad Industry Backing
April 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





